Influence of Hemodialysis on Acyclovir Pharmacokinetics in Patients with Chronic Renal Failure
Overview
Affiliations
The pharmacokinetic disposition of acyclovir was studied in six patients with chronic renal failure (CRF) and anuria. At the end of a one-hour intravenous infusion (2.5 mg/kg), the mean peak acyclovir plasma level (+/- SD), determined by radioimmunoassay, was 37.5 +/- 24.2 microM (8.4 +/- 5.4 microgram/ml), twice the level found at this dose in patients with normal renal function (NRF). In the CRF volunteers, significant plasma levels (3.0 +/- 1.4 microM) persisted at 47 hours after drug administration (before hemodialysis) whereas in the NRF patients levels dropped to less than 1 microM by 11 hours. Hemodialysis was started 47 hours after infusion and was continued for six hours. The pre-dialysis plasma drug level was reduced by 61.5 percent at 0.25 to 1.5 hours after the end of dialysis. The mean plasma t 1/2 during dialysis of 5.4 hours, the extraction ratio of 0.44, and the dialysis clearance for plasma of 113 ml/min indicate that acyclovir is efficiently removed by hemodialysis. One-half the suggested intravenous dose for a particular indication can be given every 24 hours and a similar replacement dose should be given after each dialysis.
An Unusual Neurological Syndrome in a Haemodialysis Patient.
Jose N, Jayaprakash V, Deiva A, Jayakumar M Indian J Nephrol. 2021; 31(3):293-295.
PMID: 34376947 PMC: 8330665. DOI: 10.4103/ijn.IJN_11_20.
A Unique Case of Valacyclovir Toxicity and Pseudobulbar Affect in a Patient On Peritoneal Dialysis.
Memon W, Rose E, Akram A, Simba B Cureus. 2021; 13(2):e13494.
PMID: 33777579 PMC: 7990347. DOI: 10.7759/cureus.13494.
Sadjadi S, Regmi S, Chau T Am J Case Rep. 2018; 19:1459-1462.
PMID: 30531673 PMC: 6298245. DOI: 10.12659/AJCR.911520.
The use of antiviral drugs during the neonatal period.
Whitley R Clin Perinatol. 2012; 39(1):69-81.
PMID: 22341538 PMC: 3290126. DOI: 10.1016/j.clp.2011.12.004.
Comparative pharmacokinetics of antiviral nucleoside analogues.
Morse G, Shelton M, ODonnell A Clin Pharmacokinet. 1993; 24(2):101-23.
PMID: 8453821 DOI: 10.2165/00003088-199324020-00002.